Replies to post #3911 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Largest Biopharmaceutical Classes
(Sales figures are worldwide for 2006.)

01* EPO $11.9B (Aranesp, Epogen, Procrit, NeoRecormon)
02. Cancer mAbs $10.6B (Rituxan, Avastin, Herceptin, Erbitux, etc.)
03. TNF-a $10.3B (Remicade, Enbrel, Humira)
04. Insulin and analogs $10.0B (many products)
05. Recombinant plasma proteins $4.7B (e.g. NovoSeven)
06. Interferon beta $4.4B (Avonex, Rebif, Beteseron)
07. G-CSF $4.4B (Neupogen, Neulasta)
08* hGH $2.5B (many products)
09. Interferon alpha $2.3B (Pegasys, Peg-Intron)
10. Enzyme replacement $1.7B (e.g. Cerezyme)
11. Antiviral mAb $1.1B (Synagis)
12. FSH $1.0B (Gonal-f, Puregon)

Total 2006 sales of these classes: approximately $65B.

*Follow-on biologic has been approved.

Source: http://www.pipelinereview.com/Top_20_Biologics_by_La_Merie.pdf